Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Dr Reddys Laboratories ADR repsg 1 Ord Shs RDY

Healthcare
Dr. Reddy’s Laboratories Limited is an India-based global pharmaceutical company. The Company offers a portfolio of products and services, including active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC). Its major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. The... see more

Recent & Breaking News (NYSE:RDY)

Dr. Reddy's Laboratories Announces the Launch of Hervycta® (trastuzumab biosimilar) in India

Business Wire July 26, 2018

Dr. Reddy’s Announces the Launch of Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg in the U.S. Market

Business Wire July 20, 2018

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy’s Laboratories Ltd. – RDY

GlobeNewswire July 18, 2018

Dr. Reddy's Laboratories announces its intent to appeal court decision in preliminary injunction hearing for Buprenorphine and Naloxone Sublingual Film

Business Wire July 14, 2018

Dr. Reddy's Laboratories Announces the Launch of Hydroxychloroquine Sulfate Tablets, USP in the U.S. Market

Business Wire July 11, 2018

Dr. Reddy's to Release Q1 FY19 Results on July 26, 2018

Business Wire July 5, 2018

Dr. Reddy's Laboratories Announces the Launch of Levetiracetam in Sodium Chloride Injection in the U.S. Market

Business Wire June 19, 2018

Dr. Reddy's Laboratories defends its right to launch Buprenorphine and Naloxone Sublingual Film in the U.S. Market

Business Wire June 16, 2018

Dr. Reddy’s Laboratories Limited announces filing of Annual Report on Form 20-F

Business Wire June 16, 2018

Dr. Reddy's Laboratories announces USFDA final approval and launch of Buprenorphine and Naloxone Sublingual Film in the U.S. Market

PR Newswire June 15, 2018

Dr. Reddy's Laboratories Announces USFDA Final Approval and Launch of Buprenorphine and Naloxone Sublingual Film in the U.S. Market

Business Wire June 14, 2018

Dr. Reddy's Laboratories Limited to present at the Goldman Sachs 39th Annual Global Healthcare Conference

Business Wire June 9, 2018

Dr. Reddy's Laboratories Limited to Present at the Jefferies 2018 Healthcare Conference

Business Wire June 5, 2018

Dr. Reddy’s Q4 and FY18 Financial Results

Business Wire May 22, 2018

Dr. Reddy's to Release Q4 and Full Year FY18 Results on May 22, 2018

Business Wire April 25, 2018

Dr. Reddy's Laboratories and its U.S. subsidiary Promius Pharma announce the filing of an NDA for its migraine candidate

Business Wire April 2, 2018

Dr. Reddy's Laboratories Announces Senior Leadership Changes

Business Wire March 29, 2018

Dr. Reddy's Laboratories Announces the Launch of Palonosetron Hydrochloride Injection in the U.S. Market

Business Wire March 26, 2018

Dr. Reddy's Laboratories Announces the Launch of Levocetirizine Dihydrochloride Tablets USP, 5 mg in the U.S. Market

Business Wire March 16, 2018

Dr. Reddy's Laboratories Announces the Launch of Tetrabenazine Tablets in the U.S. Market

Business Wire February 2, 2018